Discover a recent study from 12 hospitals across China that has shed new light on personalised care for plaque psoriasis.

And beyond the physical symptoms, plaque psoriasis also frequently has negative effects on mental health and alters the lifestyle of those living with it. Here are five ways that this skin condition ...

A recent cohort study suggests physical activity may improve psoriasis severity and cardiovascular health, showing reduced PASI scores and better BP.

Research shows lifestyle changes like diet, exercise, and smoking cessation can assist with improving psoriasis outcomes and ...

Johnson & Johnson (NYSE: JNJ) announced today that treatment with TREMFYA® (guselkumab) resulted in clear or almost clear ...

Treats plaque ... with psoriasis might gravitate toward salicylic acid products because they can help reduce the scaling and ...

Opens in a new tab or window PD-1 and PD-L1 immune checkpoint inhibitors (ICIs) for treating advanced cancer were associated with an increased risk of new-onset psoriasis, a large observational study ...

Data from the Phase 3b SPECTREM study to measure skin clearance and other treatment outcomes in low BSA moderate PsO with ...

A new study aimed to explore the role of stress hyperglycemia ratio (SHR) in predicting mortality risks for patients with ...

New phase 3b data reveal significant skin clearance in historically underserved patients with moderate plaque psoriasis, offering hope for improved treatment outcomes.

Affecting more than 125 million people worldwide, plaque psoriasis is an immune-mediated disease characterised by inflamed, scaly plaques that may be itchy or painful. Sensitive or highly visible ...

(RTTNews) - Johnson & Johnson (JNJ) Friday announced positive results from Phase 3b SPECTREM study of Tremfya to treat adults with low body surface area (BSA) moderate plaque psoriasis (PsO) in ...